Severe pulmonary adverse effects in lymphoma patients treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) regimen plus rituximab

Korean Journal of Internal Medicine

Volumn 25, Issue 1, 2010, Pages 86-92

  Lim, Kyu Hyoung ^a   Yoon, Ho Il ^b   Kang, Young Ae ^b   Lee, Keun Wook ^b   Kim, Jee Hyun ^b   Bang, Soo Mee ^b   Lee, Jae Ho ^b   Lee, Choon Taek ^a,b   Lee, Jong Seok ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Adverse effects; Drug therapy; Lung diseases, interstitial; Lymphoma, non hodgkin; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PARACETAMOL; PHENIRAMINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; FEMALE; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; LUNG INFECTION; LUNG PARENCHYMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; SMOKING; TUBERCULOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INCIDENCE; LUNG DISEASES, INTERSTITIAL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUBERCULOSIS, PULMONARY; VINCRISTINE; YOUNG ADULT;

EID: 77949362077     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.1.86     Document Type: Article

References (19)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
2. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-473.
3. Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2:378-384.
4. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001;42:1329-1337.
5. Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin C Jr, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma 2003;4:36-42.
6. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
8. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348:2690-2691.
9. Swords R, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004;77:103-104.
10. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004;79:949, 953.
11. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-919.
12. Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol. 2008;87:393-397.
13. Lee Y, Kyung SY, Choi SJ, et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006;21:183-186.
14. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-7368.
15. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-811.
16. Alho HS, Maasilta PK, Harjula AL, Hammainen P, Salminen J, Salminen US. Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2003;76:516-523.
17. Tonelli AR, Lottenberg R, Allan RW, Sriram PS. Rituximabinduced hypersensitivity pneumonitis. Respiration 2009;78:225-229.
18. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29(1 Suppl 2):36-40.
19. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691-2694.